{"product_id":"rigel-five-forces-analysis","title":"Rigel Pharmaceuticals Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFrom Overview to Strategy Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eRigel Pharmaceuticals faces high competitive rivalry and moderate supplier power amid a pipeline-driven biotech landscape where regulatory hurdles and payer negotiation shape margins; buyer power and threat of substitutes vary by indication, while barriers to entry remain significant but evolving with biotech innovation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Contract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRigel Pharmaceuticals depends on specialized contract manufacturing organizations (CMOs) for small-molecule drugs like fostamatinib and olutasidenib; only a handful of CMOs meet the complex synthesis and FDA cGMP standards, limiting supplier options.\u003c\/p\u003e\n\u003cp\u003eThat scarcity gives CMOs moderate bargaining power over pricing and schedules; for orphan-designated batches (often \u0026lt;10% of total volumes), smaller runs raise per-unit costs and increase schedule sensitivity—CMO price uplifts of 10–25% are common in industry benchmarks through 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliance on Single-Source API Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRigel often relies on a handful of single-source API suppliers for key active pharmaceutical ingredients, creating concentration risk; in 2025 roughly 65% of its critical APIs came from two vendors. Switching suppliers demands months-long regulatory revalidation and can take 6–12+ months, raising operational costs and delaying product launches. That dependency boosts supplier bargaining power—any supply disruption or a 10–20% price increase would cut margins and limit market availability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Organization Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRigel relies on specialized clinical research organizations (CROs) for RIPK1 and signaling-pathway trials; CROs control rare-disease patient networks and global sites, raising their leverage. In 2024, top CROs captured ~45% of rare-disease trial sites and charge 10–30% premium for global Phase II\/III studies, boosting supplier bargaining power. Their regulatory know-how on FDA\/EMA guidance lets them demand tighter contract terms and milestone-linked fees.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Lab Equipment and Reagents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpecialized lab tools and proprietary reagents are core to Rigel Pharmaceuticals early discovery and QA; suppliers like Thermo Fisher Scientific and Agilent held ~28% and ~12% global market share in lab instruments in 2024, giving patent-backed pricing power that limits Rigel’s switching options.\u003c\/p\u003e\n\u003cp\u003eHigh capital and consumable costs—bench equipment CAPEX plus recurring reagent spend often \u0026gt;$5M\/yr for a mid-size biotech—mean suppliers can sustain premium prices and long-term contracts, squeezing Rigel’s margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatented instruments restrict substitutes\u003c\/li\u003e\n\u003cli\u003eThermo Fisher ~28% market share (2024)\u003c\/li\u003e\n\u003cli\u003eMid-size biotech lab costs \u0026gt;$5M\/yr\u003c\/li\u003e\n\u003cli\u003eSuppliers set premium prices, raising input risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccess to Specialized Human Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpthe supply of highly skilled scientists and regulatory experts is a critical input for rigel pharmaceuticals competition in biotech hubs like san francisco pushed median salaries up about from reaching roughly increasing labor costs giving suppliers leverage.\u003e\n\u003cpthis tight labor market through forces rigel to offer competitive equity and cash packages total compensation for senior scientists ranges workforce bargaining power remains high raising r burn rates diluting equity.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003eMedian biotech salary 2024: ~$160,000\u003c\/li\u003e\u003cli\u003eSenior scientist total comp: $220k–$320k\u003c\/li\u003e\u003cli\u003eSalary growth 2020–2024: ~12%\u003c\/li\u003e\n\u003c\/pthis\u003e\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier dominance and rising biotech costs squeeze R\u0026amp;D — concentrated vendors, fat salaries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold moderate–high power: concentrated CMOs\/APIs (65% from two vendors in 2025), CROs commanding ~45% rare-disease sites and 10–30% premiums, and dominant lab vendors (Thermo Fisher ~28% market share, 2024) raise costs; switching\/revalidation takes 6–12+ months. Tight labor pushed median biotech pay to ~$160,000 (2024), raising R\u0026amp;D burn and supplier leverage.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI concentration (2025)\u003c\/td\u003e\n\u003ctd\u003e65% from 2 vendors\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO site share (2024)\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eThermo Fisher (2024)\u003c\/td\u003e\n\u003ctd\u003e~28% market share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian biotech salary (2024)\u003c\/td\u003e\n\u003ctd\u003e~$160,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis of Rigel Pharmaceuticals, uncovering competitive drivers, buyer and supplier power, threat of new entrants and substitutes, and strategic vulnerabilities that affect its pricing, profitability, and market positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise Porter's Five Forces snapshot tailored to Rigel Pharmaceuticals—ideal for quick strategic decisions and slide-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Pharmacy Benefit Managers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe US pharmacy benefit manager (PBM) market is highly concentrated: three firms—CVS Caremark, Express Scripts (Cigna), and Optum Rx—manage roughly 70% of commercial formularies as of 2025, letting them demand steep rebates and discounts from manufacturers like Rigel Pharmaceuticals. If a major PBM excludes a Rigel drug from its preferred tier, Rigel can lose access to millions of insured patients and material revenue; for context, PBM-negotiated rebates can exceed 30% of list price on specialty drugs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Payers and Pricing Legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpwith the continued implementation of drug pricing reforms through government programs like medicare have increased power to negotiate prices.\u003e\n\u003cprigel products particularly those serving chronic immune conditions are subject to federal reimbursement caps that took effect in limiting average selling price growth roughly annually versus historical\u003e\n\u003cpthis regulatory shift moves pricing power toward the state constraining rigel ability to set premium prices and pressuring margin forecasts in\u003e\n\u003c\/pthis\u003e\u003c\/prigel\u003e\u003c\/pwith\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Specialized Hematology Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe market for Rigel Pharmaceuticals’ oncology and hematology drugs is concentrated among a few specialized hospitals and oncology networks that account for roughly 60–75% of channel volume in key US niches as of 2025; these systems can demand volume discounts of 5–20% and preferential formulary placement.\u003c\/p\u003e\n\u003cp\u003eBecause Rigel targets narrow indications, losing one large network (10–25% of commercial revenue per network based on 2024 sales patterns) would meaningfully cut top-line revenue and weaken negotiating leverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy and Information Accessibility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cppatients now research treatments online and join advocacy groups surveys show of rare-disease patients report group influence on insurer decisions so rigel must engage these networks to secure coverage uptake.\u003e\n\u003cpadvocacy groups pushed price concessions in specialty drugs faced expanded-access campaigns nonengagement risks public pressure formulary exclusion or mandated access programs that hit revenues.\u003e\n\u003cpmaintaining trust transparent pricing and patient-program funding can protect launch roi patient groups sway thousands of prescribers affect peak sales that often top for niche biologics.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e68% patient influence on insurer priorities (2024 survey)\u003c\/li\u003e\n\u003cli\u003e12 specialty drugs pressured for expanded access in 2023\u003c\/li\u003e\n\u003cli\u003eTypical niche biologic peak sales ≈ $200M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pmaintaining\u003e\u003c\/padvocacy\u003e\u003c\/ppatients\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of Alternative Treatment Pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePhysicians, as primary prescribers, can shift from Rigel’s drugs to alternatives if competitors offer similar efficacy with better safety or lower cost; a 2024 IQVIA report showed 28% of prescribers switched within 12 months when safety data favored rivals.\u003c\/p\u003e\n\u003cp\u003eThat professional discretion forces Rigel to spend heavily on trials and education—Rigel’s 2024 R\u0026amp;D and SG\u0026amp;A were $132.4M combined—to retain prescribing loyalty.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhysician-led choice drives demand\u003c\/li\u003e\n\u003cli\u003e28% switch rate when safety beats efficacy\u003c\/li\u003e\n\u003cli\u003eSafety\/price trump similar efficacy\u003c\/li\u003e\n\u003cli\u003eRigel spent $132.4M on R\u0026amp;D+SG\u0026amp;A in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated Buyers Squeeze Pharma: Rebates \u0026gt;30%, ASP Growth Capped, Losses = 10–25%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers—large PBMs (CVS, Cigna\/Express Scripts, Optum) controlling ~70% of formularies, Medicare negotiating power post-2025, and concentrated hospital\/oncology networks (60–75% channel share)—wield strong leverage, forcing rebates \u0026gt;30%, volume discounts 5–20%, and capping ASP growth to ~2% annually; losing one network (10–25% rev) or failing patient\/advocacy engagement risks sharp revenue hits.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBuyer\u003c\/th\u003e\n\u003cth\u003eShare\/Impact\u003c\/th\u003e\n\u003cth\u003eKey Metrics (2024–25)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBMs\u003c\/td\u003e\n\u003ctd\u003e~70% formularies\u003c\/td\u003e\n\u003ctd\u003eRebates \u0026gt;30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare\u003c\/td\u003e\n\u003ctd\u003eNegotiation power\u003c\/td\u003e\n\u003ctd\u003eASP growth capped ~2% (post-2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\/networks\u003c\/td\u003e\n\u003ctd\u003e60–75% channel\u003c\/td\u003e\n\u003ctd\u003eDiscounts 5–20%; loss = 10–25% revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eRigel Pharmaceuticals Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Rigel Pharmaceuticals Porter's Five Forces analysis you'll receive immediately after purchase—no surprises, no placeholders.\u003c\/p\u003e\n\u003cp\u003eThe document displayed here is part of the full, professionally formatted report and will be available for instant download the moment you buy.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the final deliverable: the same comprehensive, ready-to-use file you'll get upon completing payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747352850809,"sku":"rigel-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/rigel-five-forces-analysis.png?v=1772197638","url":"https:\/\/matrixbcg.com\/products\/rigel-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}